New Delhi, November 06, 2023: Supriya Lifescience, one of India’s leading speciality active pharmaceutical ingredients (API) manufacturing company and CDMO signs an agreement with Kalinga Institute of Technology for further development of GelHeal, a protein-based crosslinked Hydrogel. The gel-based cream is mapped out and designed taking into account the In-Situ scaffolding for mechanical support into the deep wounds and scar-free skin regeneration.

The gel-based cream may prove to be prolific in easing and healing not only third-degree wounds, cuts, bite/ballistic wounds but also diabetic foot ulcers, pressure ulcers, venous leg ulcers and surgery wounds.

This radical shift in dermatology and skin grafting would also now cater to scar-free skin, not mandating repetitive hospitalization through the topical formulation for skin regeneration gel, thus proving cost cost-effective and less time-consuming medical solution for many.

With such functionalities, GelHeal also fabricates mechanisms for preventing infection, avoiding over-drying while accommodating a moist environment, mechanical support for strain-less wound closure and Scaffold Support Skin Regeneration Support thus resulting in scar-free skin.

Dr. Satish Wagh, Founder and Chairman, Supriya Lifescience Ltd says, “As we have already demarcated positive change by recently signing an agreement to develop Quickblue which is the oral cancer detection kit in collaboration with Kalinga Institute of Industrial Technology, we are looking forward in aiding more innovative products like GelHeal, the simplest and cheapest wound healing gel”.

Dr. Satish Wagh further said, “Supriya Lifescience has established itself as a CDMO player over decades,  Supriya Lifescience is putting a step forward into diversification of our business by banking on our world-class CDMO capabilities and offering niche products for healthcare needs. We believe more and more of such products will establish Supriya Lifescience Ltd as an integrated healthcare provider.”

The post Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for further development of wound healing gel appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

New Delhi, October 23, 2023: Supriya Lifescience Ltd, the Mumbai-based and one of the prominent specialized active pharmaceutical ingredients (API) manufacturing Company, has collaborated with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, to develop one of its kind oral cancer detection kit named Quickblue oral kit.

This oral cancer detection kit is designed to detect oral cancer in a cost-effective and efficient manner. This kit seamlessly detects oral cancer and could potentially reduce the need for extensive preclinical and clinical trials. The company has also filed for the patent of the Quickblue oral kit.

Dr Satish Wagh, Chairman, Supriya Lifescience Ltd, estimates that the Quickblue oral kit could reduce the cost of oral cancer detection significantly, eliminating the need for multiple biopsies in cases of non-healing oral ulcers.

“The high prevalence of oral cancer, with millions of cases reported globally, underscores the importance of early detection. This product is particularly relevant in India and the Asian sub-continent, where a significant percentage of oral cancer patients are found.”

“Early detection of cancer is crucial for improving treatment outcomes, and the Quickblue oral kit can contribute to saving lives by identifying oral cancer at an early stage. The development of the Quickblue oral kit is a promising advancement in the field of healthcare, with the potential to make oral cancer detection more accessible, cost-effective, and lifesaving. It addresses a critical healthcare need and underscores the importance of innovation in the pharmaceutical and healthcare industry.”

Dr. Wagh also mentions, “The development of an oral cancer detection kit is in line with Supriya Lifescience’s vision of manufacturing niche products to meet unmet medical needs. This initiative represents a step towards diversifying the product portfolio of Supriya Lifescience Ltd. The company aims to expand and scale to new heights over the next decade.”

Commenting on the development of Quickblue, Dr Mrutyunjay Suar, Director General R&D and Innovation, Kalinga Institute of Industrial Technology (KIIT) University, said, “We are extremely proud to be part of this journey of collaborating with Supriya Lifescience Ltd for such a novel product. KIIT is committed to high-quality research and provides outstanding facilities and a supportive environment for our academics and students. KIIT’s research portfolio extends across many different areas including, biotechnology, medicine; rural management; physical activity and nutrition; education; and social and mental health. KIIT has placed much emphasis on creating enabling infrastructure and facilities for advanced research in diverse areas. Our research groups of scholars and faculty members worked relentlessly with the expert team of Supriya Lifescience to develop this product. We believe this product can be a lifesaver by early detection of oral cancer.”

The post Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for development of first-of-its-kind novel oral cancer detection kit appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.